生命科学资讯

Hims says it will stop selling GLP-1 pill, after legal pressure from US

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS

Taking A Fresh Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Weakness - simplywall.st

Agilent’s SLAS2026 Automation Push Might Change The Case For Investing In Agilent Technologies (A) - simplywall.st

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks

Illumina (ILMN) One Off Gain Shapes Profitability Narrative After FY 2025 Earnings - simplywall.st

Illumina Earnings Call Highlights Clinical Growth Momentum - TipRanks

US calls for DOJ investigation of Hims over GLP-1 drugs

AGILENT TECHNOLOGIES, INC. ($A) CEO 2025 Pay Revealed - Quiver Quantitative

TrumpRx launch falls flat for some, citing generic access

Key facts: Illumina Q4 2025 revenue rises to $1.16B; 2026 growth forecasted - TradingView

UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge

Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals

HHS drops legal fight over blocked 340B rebate pilot

Orphan drug tweak in US spending bill will make life easier for the FDA

White House’s online service for drug sales debuts with limited impact on prices

Illumina Enters Oversold Territory (ILMN) - Nasdaq

Idorsia gets FDA-backed route to approval for oral Fabry drug

More biopharma IPOs: Agomab raises $200M, Spyglass gets $150M